Skip to content
Keytruda(pembrolizumab)
Keytruda (pembrolizumab) is an antibody pharmaceutical. Pembrolizumab was first approved as Keytruda on 2014-09-04. It is used to treat hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat endometrial neoplasms, hodgkin disease, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma amongst others. The pharmaceutical is active against programmed cell death protein 1.
Download report
Favorite
COVID-19
Drugs Approved for Childhood Cancers
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
genetic phenomenaD055614
Trade Name
FDA
EMA
Keytruda
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Pembrolizumab
Tradename
Proper name
Company
Number
Date
Products
KeytrudapembrolizumabMerck Sharp & DohmeN-125514 RX2015-01-15
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
keytrudaBiologic Licensing Application2021-03-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hodgkin disease—D006689C81
melanoma—D008545—
microsatellite instability—D053842—
non-small-cell lung carcinoma—D002289—
squamous cell carcinoma—D002294—
ureteral neoplasmsEFO_0003844D014516C66
urethral neoplasmsEFO_0003846D014523—
urinary bladder neoplasms—D001749C67
Agency Specific
FDA
EMA
Expiration
Code
pembrolizumab, Keytruda, Merck Sharp & Dohme LLC
2028-12-03Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF02: Pembrolizumab
HCPCS
Code
Description
J9271
Injection, pembrolizumab, 1 mg
Clinical
Clinical Trials
1871 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022891461805829334
MelanomaD00854511612415110211
Squamous cell carcinoma of head and neckD0000771956698514149
Pancreatic neoplasmsD010190EFO_0003860C25393711—66
GlioblastomaD005909EFO_00005151422—1131
ThymomaD0139451——1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C802151252—3264
Breast neoplasmsD001943EFO_0003869C5058826—2126
Colorectal neoplasmsD01517963646—2109
Triple negative breast neoplasmsD06472650607——99
Renal cell carcinomaD00229258506—493
Ovarian neoplasmsD010051EFO_0003893C5639543—180
Stomach neoplasmsD013274EFO_0003897C1639466——74
Head and neck neoplasmsD00625830489——71
Lung neoplasmsD008175C34.90344011—367
Liver neoplasmsD008113EFO_1001513C22.028356—464
Show 43 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcomaD0125091522———28
LymphomaD008223C85.91911———24
Non-hodgkin lymphomaD008228C85.91614———23
Large b-cell lymphoma diffuseD016403C83.31215———23
Castration-resistant prostatic neoplasmsD0641291013———20
CholangiocarcinomaD018281C22.11112———18
Follicular lymphomaD008224C821110———17
Myeloid leukemia acuteD015470C92.099———16
Pancreatic ductal carcinomaD021441310———11
Hepatocellular carcinomaD006528C22.058———10
Show 126 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lymphoid leukemiaD007945C912————2
Hiv infectionsD015658EFO_0000764B202————2
Digestive system neoplasmsD0040672————2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Myelomonocytic leukemia chronicD015477C93.11————1
AnemiaD000740EFO_0004272D64.91————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.21————1
ThrombocytosisD013922D75.831————1
B-cell leukemiaD0154481————1
PharmacokineticsD0105991————1
Show 16 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K77————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePEMBROLIZUMAB
INNpembrolizumab
Description
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)PEMBROLIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>5GGS:A,C|heavy chain QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAY MELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH >5GGS:B,D|light chain EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTIS SLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5B8C, 5DK3, 5GGS, 5JXE
CAS-ID1374853-91-4
RxCUI1547545
ChEMBL IDCHEMBL3137343
ChEBI ID—
PubChem CID—
DrugBankDB09037
UNII IDDPT0O3T46P (ChemIDplus, GSRS)
Target
Agency Approved
PDCD1
PDCD1
Organism
Homo sapiens
Gene name
PDCD1
Gene synonyms
PD1
NCBI Gene ID
5133
Protein name
programmed cell death protein 1
Protein synonyms
CD279, programmed cell death 1 protein, protein PD-1, systemic lupus erythematosus susceptibility 2
Uniprot ID
Q8IX89
Mouse ortholog
Pdcd1 (18566)
programmed cell death protein 1 (Q02242)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Keytruda - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 47,111 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,697 adverse events reported
View more details